Copilot
Using
the web
Certainly! Let’s explore the fascinating collaboration between Ginkgo Bioworks and Pfizer:
Ginkgo Bioworks and Pfizer Collaboration:
Announcement: On September 27, 2023, Ginkgo Bioworks (NYSE: DNA) and Pfizer (NYSE: PFE) announced a multi-target RNA discovery collaboration.
Focus: The collaboration centers around the discovery of RNA-based drug candidates.
Ginkgo’s Proprietary RNA Technology: Pfizer will leverage Ginkgo’s proprietary RNA technology to advance the discovery and development of novel RNA molecules across priority research areas.
Financial Terms:
Ginkgo will receive an upfront payment.
They are eligible for research fees and development and commercial milestone payments, totaling up to $331 million across three programs.
Ginkgo may also receive royalties on sales1.
RNA Therapeutics: RNA therapeutics encode proteins with the potential to treat or cure diseases. This approach represents an exciting new avenue in medicine.
Ginkgo’s Approach: Ginkgo combines high-throughput screening of RNA constructs with a multi-parameter design framework. Their goal is to identify optimal natural and synthetic elements for specific applications, ensuring efficient production, stability, and enhanced translation of each RNA construct.
Pfizer’s Perspective: Pfizer recognizes the importance of RNA therapeutics and aims to search for novel RNA constructs with improved stability and expression for more effective treatments.
Programmable Medicines: Ginkgo’s broad RNA Codebase and Foundry enable the era of programmable medicines in collaboration with Pfizer1.
In summary, this collaboration exemplifies how cutting-edge biotechnology companies like Ginkgo Bioworks and pharmaceutical giants like Pfizer join forces to advance scientific innovation and therapeutic solutions. 🌱🔬💊
